Brief: Formycon AG - Clinical Development Of FYB206 Completed In July 2026
22/09/2026 05:31
BRIEF-Formycon AG - Clinical Development Of FYB206 Completed In July 2026 Sept 22 (Reuters) - FORMYCON AG FYB.DE:
EQS-NEWS: FORMYCON SETS BENCHMARK IN BIOSIMILAR DEVELOPMENT: SCIENTIFIC FOUNDATION OF THE INNOVATIVE DEVELOPMENT PROGRAM FOR FYB206 PUBLISHED IN THE JOURNAL BIODRUGS
FORMYCON AG - CLINICAL DEVELOPMENT OF FYB206 SUCCESSFULLY COMPLETED IN JULY 2026
FORMYCON AG - FYB206 DEMONSTRATES PHARMACOKINETIC EQUIVALENCE TO KEYTRUDA IN PIVOTAL DAHLIA STUDY
Source text: ID:nEQ8nlt1ca
Further company coverage: FYB.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Formycon AG
See all newsBrief: Formycon Says Fyb286 Expands Formycon Biosimilar Pipeline Targeting Niche Indication
Brief: FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE
Brief: Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
Brief: Formycon AG - Clinical Development Of FYB206 Completed In July 2026
Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows